Evidence map›Paper›PMID 35216507›Full record

ArticleInternational journal of molecular sciences2022

Discovery of SARS-CoV-2 3CL

Yaxin Wang, Binghong Xu, Sen Ma, Hao Wang, Luqing Shang, Cheng Zhu, Sheng Ye

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Exploring the Therapeutic Potential ofMolecules (Basel, Switzerland) · 2024
    Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yaxin WangTianjin Key Laboratory of Function and Application of Biological Macromolecular Structures, School of Life Sciences, Tianjin University, Tianjin 300072, China.
Binghong XuTianjin Key Laboratory of Function and Application of Biological Macromolecular Structures, School of Life Sciences, Tianjin University, Tianjin 300072, China.ORCID 0000-0002-0137-3381
Sen MaTianjin Key Laboratory of Function and Application of Biological Macromolecular Structures, School of Life Sciences, Tianjin University, Tianjin 300072, China.
Hao WangKLMDASR of Tianjin and Drug Discovery Center for Infectious Disease, State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300353, China.
Luqing ShangKLMDASR of Tianjin and Drug Discovery Center for Infectious Disease, State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300353, China.
Cheng ZhuTianjin Key Laboratory of Function and Application of Biological Macromolecular Structures, School of Life Sciences, Tianjin University, Tianjin 300072, China.ORCID 0000-0003-0260-6287
Sheng YeTianjin Key Laboratory of Function and Application of Biological Macromolecular Structures, School of Life Sciences, Tianjin University, Tianjin 300072, China.ORCID 0000-0001-9300-6257
Tianjin University · CNNankai University · CN

Funding

National Key Research and Development Program of China 2020YFA0908500, 2020YFA0908501National Natural Science Foundation of China 22007071, 31971127, and 81801998
6 · The paper itself

Abstract

As the etiological agent for the coronavirus disease 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) challenges the ongoing efforts of vaccine development and drug design. Due to the accumulating cases of breakthrough infections, there are urgent needs for broad-spectrum antiviral medicines. Here, we designed and examined five new tetrapeptidomimetic anti-SARS-CoV-2 inhibitors targeting the 3C-Like protease (3CL

Indexed as

AnimalsAntiviral AgentsCatalytic DomainChlorocebus aethiopsCoronavirus 3C ProteasesCOVID-19 Drug TreatmentDrug DesignFluorescence Resonance Energy TransferHistidineLigandsMolecular Dynamics SimulationPeptidomimeticsProtease InhibitorsSARS-CoV-2Structure-Activity RelationshipVero Cells3C-like proteinase, SARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesHistidineLigandsPeptidomimeticsProtease Inhibitorscovalent inhibitormolecular dynamics simulationsmolecule designSARS-CoV-2

Identifiers

PMID35216507
PMCPMC8878928
OpenAlexW4213194947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.